Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) Equity Ratio: 2019-2025

Historic Equity Ratio for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to 0.73.

  • Summit Therapeutics' Equity Ratio fell 15.65% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year decrease of 15.65%. This contributed to the annual value of 0.89 for FY2024, which is 133.15% up from last year.
  • Summit Therapeutics' Equity Ratio amounted to 0.73 in Q3 2025, which was down 8.25% from 0.80 recorded in Q2 2025.
  • Summit Therapeutics' Equity Ratio's 5-year high stood at 0.90 during Q1 2025, with a 5-year trough of 0.19 in Q4 2022.
  • Moreover, its 3-year median value for Equity Ratio was 0.57 (2024), whereas its average is 0.63.
  • Per our database at Business Quant, Summit Therapeutics' Equity Ratio slumped by 74.04% in 2022 and then skyrocketed by 258.72% in 2025.
  • Summit Therapeutics' Equity Ratio (Quarterly) stood at 0.73 in 2021, then tumbled by 74.04% to 0.19 in 2022, then surged by 100.75% to 0.38 in 2023, then soared by 133.15% to 0.89 in 2024, then declined by 15.65% to 0.73 in 2025.
  • Its Equity Ratio was 0.73 in Q3 2025, compared to 0.80 in Q2 2025 and 0.90 in Q1 2025.